Two-year follow-up results from an ongoing study on the safety and effectiveness of elexacaftor/tezacaftor/ivacaftor when used in real-world settings by people with cystic fibrosis
A letter in response to the recently published article entitled “Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis
Association between nebulizer therapies adherence and visit-to-visit variability of lung function in patients with cystic fibrosis
The Completion of Airway Clearance Therapy at School in a Group of Pediatric Patients with Cystic Fibrosis
Increased blood glucose during the night is associated with a lower pulmonary function in adults but not in children with cystic fibrosis.
The effects of Trikafta/Kaftrio on people with CF who have mutations other than the most common CF mutation (F508del)
Tobacco Smoke Exposure and Socioeconomic Factors Are Independent Predictors of Pulmonary Decline in Pediatric Cystic Fibrosis
